Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials

Metabolism: Clinical and Experimental
Amirhossein SahebkarSimona Bo

Abstract

The effect of statins on plasma concentrations of vascular endothelial growth factor (VEGF), the main angiogenic growth factor with pro-inflammatory and atherogenic properties, is controversial. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to obtain a conclusive result in humans. PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched to identify RCTs investigating the impact of statins on plasma VEGF concentrations. A random-effects model and the generic inverse variance method were used for quantitative data synthesis. Meta-regression, sensitivity analysis and publication bias assessments were performed using standard methods. Eight RCTs examining the effects of statins on plasma VEGF concentrations were included. Meta-analysis suggested a significant reduction of plasma VEGF levels following statin therapy (weighed mean difference: -19.88 pg/mL, 95% CI: -35.87, -3.89, p=0.015). VEGF reductions were observed in the subsets of trials with treatment durations ≥4 weeks (-19.54, -37.78, -1.30, p=0.036), LDL-C reductions ≥50 mg/dL (-28.59, -43.68, -13.50, p<0.001), lipophilic statins (-22.31, -40.65, -3.98, p=0.017), and diseased populations (-21.08, -39.97, -...Continue Reading

References

Aug 8, 2001·The Journal of Clinical Investigation·S DimmelerA M Zeiher
Jan 5, 2002·Annals of Internal Medicine·Saul Benedict Freedman, Jeffrey M Isner
Jan 17, 2002·Current Treatment Options in Cardiovascular Medicine·Tanveer A. KhanRoger J. Laham
Jun 27, 2002·Journal of the American College of Cardiology·Hannes Franz AlberFranz Weidinger
Feb 5, 2003·Circulation·Christopher HeeschenUNKNOWN CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators
Feb 20, 2003·European Heart Journal·P O BonettiA Lerman
Mar 19, 2003·Circulation·Timothy D HenryUNKNOWN VIVA Investigators
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Apr 13, 2004·Journal of Cardiovascular Pharmacology·Hiroyuki MatsunoOsamu Kozawa
Nov 6, 2004·Current Opinion in Lipidology·Kausik K Ray, Christopher P Cannon
Dec 2, 2004·Journal of Molecular and Cellular Cardiology·A J SiddiquiC Sylvén
Apr 28, 2005·International Journal of Clinical Practice·R Y A MukhtarJ P D Reckless
Nov 10, 2005·Menopause : the Journal of the North American Menopause Society·Nirav R ShahRobert W Dubois
Jan 21, 2006·Journal of Cardiovascular Pharmacology·Aura G GiurgeaMehrdad Baghestanian
Feb 17, 2006·Biochemical and Biophysical Research Communications·Koka MotoyamaYoshiki Nishizawa
Apr 25, 2006·Nature Reviews. Molecular Cell Biology·Anna-Karin OlssonLena Claesson-Welsh
Apr 23, 2008·Journal of Cardiovascular Pharmacology·Takamitsu NakamuraKiyotaka Kugiyama
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Oct 17, 2009·Journal of Cardiovascular Pharmacology·Cristiano SpadaccioMassimo Chello
Nov 12, 2009·American Journal of Physiology. Endocrinology and Metabolism·Yukihito HigashiTsutomu Imaizumi
Nov 21, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Osamu YoshidaToyoaki Murohara
Mar 5, 2010·Metabolism: Clinical and Experimental·Ana Lucia de Almeida KaterSandra Roberta Gouvea Ferreira
Jan 24, 2012·Journal of Clinical Lipidology·Jonathan R MurrowArshed A Quyyumi
Sep 25, 2012·Heart Failure Clinics·Jeong-a KimMichael J Quon
Aug 6, 2013·Cardiovascular Drugs and Therapy·Amirhossein Sahebkar, Gerald F Watts

❮ Previous
Next ❯

Citations

Dec 2, 2015·British Journal of Clinical Pharmacology·Amirhossein SahebkarGerald F Watts
Jun 30, 2016·Heart·Bernhard M KaessRamachandran S Vasan
Feb 7, 2017·British Journal of Clinical Pharmacology·Eva DolezelovaAmirhossein Sahebkar
Apr 12, 2017·The Journal of Clinical Endocrinology and Metabolism·Chien-Yi HsuShing-Jong Lin
Sep 12, 2018·Journal of Cellular Physiology·Anis AskarizadehAmirhossein Sahebkar
Aug 3, 2017·Journal of the American Heart Association·Shiu Lun Au YeungC Mary Schooling
Jan 9, 2019·Journal of Cellular Physiology·Maryam PasebanAmirhossein Sahebkar
Jan 15, 2019·Journal of Cellular Physiology·Amir Abbas Momtazi-BorojeniAmirhossein Sahebkar
May 7, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·Andrea Mondragón-GarcíaÓscar Pérez-Méndez
Jul 29, 2020·Journal of Clinical Medicine·Stefanos RoumeliotisCarmine Zoccali
Aug 8, 2019·Drug Development Research·Mohammad S HareedyMarwa F Ali
Jan 30, 2021·Neural Regeneration Research·Toralf Bruning, Mohamed Al-Khaled

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.